Realeve

Realeve operates in the medical-device and neuromodulation segment, with a focused application in severe headache, especially cluster headache. Its Pulsante system is described as an implant-based approach involving stimulation of the sphenopalatine ganglion (SPG), rather than a general-purpose wellness product or a conventional drug therapy. The product set also includes a handheld controller and proprietary ASIC technology for device communication, power, and therapy. The company’s 2018 registry announcement and France’s Forfait Innovation package suggest that clinical evidence and access pathways were important parts of its strategy. Its historical financing—$136.2 million in total across six rounds, including two Series D rounds in 2015—reflects a capital-intensive medical-device development path. The clearest differentiators supported by the profile are its specialized SPG stimulation focus, implant-and-controller system, and stated clinical use in severe headache. Current commercial reach and competitive standing remain unclear.

Realeve’s trajectory reflects a long medical-device development cycle rather than a recent high-growth software model. Founded in 2007, the company raised a $3 million Series A in 2008, followed by $20 million in Series B in 2009 and $32 million in Series C in 2011. Two Series D rounds in May and June 2015 added $38 million and $43.2 million, respectively; debt financing was recorded on Jan 1, 2016, bringing reported total funding to $136.2 million across six rounds. The 2018 prospective registry announcement and France’s Forfait Innovation package mark later clinical-evidence and access milestones for Pulsante Therapy. The device portfolio described in the profile includes a battery-free implant, an external handheld power/controller device, and custom ASIC technology. These developments suggest progression from technology development toward clinical validation and adoption efforts.